series-b
Stage
2009
Founded
1
Investors
About
Cantargia is a biotechnology company focused on developing antibody-based treatments for cancer and inflammatory/autoimmune diseases, primarily targeting the IL1RAP protein. Its lead candidate, nadunolimab, is in clinical trials for pancreatic cancer and other solid tumors, while a second candidate, CAN10, addresses autoimmune conditions.
Explore Cantargia's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.